SCHEMBL1702955

SCHEMBL1702955

Cc1cc(NC(=O)Nc2ccc(-c3nccc4[nH]nc(N)c34)cc2)ccc1F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 1.00
FLT3 P36888 14/20 0.74
KIT P10721 13/20 0.74
FLT4 P35916 10/20 0.74
CSF1R P07333 9/20 0.74
FLT1 P17948 9/20 0.74
LYN P07948 8/20 0.74
SRC P12931 8/20 0.74
BLK P51451 8/20 0.74
LCK P06239 8/20 0.74
FYN P06241 6/20 0.74
CDK19 Q9BWU1 3/20 0.74
PLK4 O00444 3/20 0.58
AURKA O14965 3/20 0.58
DYRK3 O43781 3/20 0.58
ROCK2 O75116 3/20 0.58
RPS6KA5 O75582 3/20 0.58
RET P07949 3/20 0.58
FGFR1 P11362 3/20 0.58
PRKACA P17612 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2237920 0.91 KDR (0.83) KDRFLT3KITFLT4CSF1R
SCHEMBL1702904 0.88 KDR (0.79) KDRFLT3KITFLT4CSF1R
SCHEMBL1703071 0.87 KDR (1.00) KDRFLT3KITFLT4CSF1R
SCHEMBL2241743 0.86 KDR (0.76) KDRFLT3KITFLT4CSF1R
SCHEMBL1702788 0.86 KDR (0.76) KDRFLT3KITFLT4CSF1R
SCHEMBL2238490 0.86 KDR (0.84) KDRFLT3KITFLT4CSF1R
SCHEMBL2240148 0.86 KDR (0.75) KDRFLT3KITFLT4CSF1R
SCHEMBL1702820 0.85 KDR (1.00) KDRFLT3KITFLT4CSF1R
SCHEMBL1702874 0.85 KDR (0.77) KDRFLT3KITFLT4CSF1R
SCHEMBL2237945 0.85 KDR (0.75) KDRFLT3KITFLT4CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP claimed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 EP claimed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US claimed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 WO claimed
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP disclosed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KDR 434/4885FLT3 79/4885KIT 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.